|
Listen to this text  |
Noah Medical introduced that its Galaxy System, an built-in system for navigated robotic bronchoscopy, was used for the primary time within the United States on the University of Chicago Medicine by Dr. Kyle Hogarth.
This process marks the primary business launch of the Galaxy System within the US following its current FDA clearance and first-in-human trials at Macquarie University Hospital in Sydney, Australia. The system was designed to offer physicians extra confidence in finding and navigating to lung nodules throughout biopsies as a part of a more practical and environment friendly bronchoscopy process.
“The Galaxy System is the first robot for peripheral lung navigation that includes integrated imaging, which is the solution bronchoscopists have been asking for,” Hogarth mentioned. “We are excited to be the first hospital in the United States to implement this next-generation robotic solution for our patients which we believe will improve and expedite the early diagnosis and treatment of lung cancer.”
The system makes use of Noah Medical’s proprietary TiLT+ Technology, which incorporates built-in tomosynthesis and augmented fluoroscopy, a single-used disposable bronchoscope, and a small, compact footprint. Noah Medical constructed TiLT+ Technology to beat CT-to-body divergency by offering real-time navigation and lesion updates with available C-arm fluoroscopy.
During the system’s first-in-human trials, physicians have supplied constructive suggestions on the system’s TiLT+ Technology, its single-use disposable bronchoscope and its small footprint.
“Congratulations to Dr. Hogarth and the team at UChicago Medicine for completing this milestone achievement in robotic bronchoscopy,” Jian Zhang, PhD, Noah Medical founder and CEO, mentioned. “We designed the Galaxy System in collaboration with physicians to provide unique clinical value to patients and improved procedural efficiency. We are thrilled to introduce the platform at UChicago Medicine, a pioneer in using life-saving technologies to fight lung cancer.”
Zhang based Noah Medical in 2018. He and Noah Medical are at present topic to litigation from Auris, which alleges the misappropriation of commerce secrets and techniques. Noah Medical has filed a movement to have the lawsuit dismissed.
Earlier this 12 months, the corporate raised $150 million in Series B funding. Noah Medical plans to make use of the funding to fulfill the rising demand for its Galaxy System, an built-in system for navigated robotic bronchoscopy.